Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma
Open Access
- 26 March 2020
- Vol. 70 (1), 157-169
- https://doi.org/10.1136/gutjnl-2019-318918
Abstract
Objective Hepatocellular carcinoma (HCC) is the fastest-growing cause of cancer-related mortality with chronic viral hepatitis and non-alcoholic steatohepatitis (NASH) as major aetiologies. Treatment options for HCC are unsatisfactory and chemopreventive approaches are absent. Chronic hepatitis C (CHC) results in epigenetic alterations driving HCC risk and persisting following cure. Here, we aimed to investigate epigenetic modifications as targets for liver cancer chemoprevention. Design Liver tissues from patients with NASH and CHC were analysed by ChIP-Seq (H3K27ac) and RNA-Seq. The liver disease-specific epigenetic and transcriptional reprogramming in patients was modelled in a liver cell culture system. Perturbation studies combined with a targeted small molecule screen followed by in vivo and ex vivo validation were used to identify chromatin modifiers and readers for HCC chemoprevention. Results In patients, CHC and NASH share similar epigenetic and transcriptomic modifications driving cancer risk. Using a cell-based system modelling epigenetic modifications in patients, we identified chromatin readers as targets to revert liver gene transcription driving clinical HCC risk. Proof-of-concept studies in a NASH-HCC mouse model showed that the pharmacological inhibition of chromatin reader bromodomain 4 inhibited liver disease progression and hepatocarcinogenesis by restoring transcriptional reprogramming of the genes that were epigenetically altered in patients. Conclusion Our results unravel the functional relevance of metabolic and virus-induced epigenetic alterations for pathogenesis of HCC development and identify chromatin readers as targets for chemoprevention in patients with chronic liver diseases.Keywords
This publication has 52 references indexed in Scilit:
- Modification of Enhancer Chromatin: What, How, and Why?Molecular Cell, 2013
- High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein–Protein InteractionJournal of the American Chemical Society, 2012
- Persistence of HCV in Quiescent Hepatic Cells Under Conditions of an Interferon-Induced Antiviral ResponseGastroenterology, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence AssessmentPLOS ONE, 2010
- Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule InhibitorCell Chemical Biology, 2010
- Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2AJournal of Hepatology, 2007
- GenePattern 2.0Nature Genetics, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Application of comparative functional genomics to identify best-fit mouse models to study human cancerNature Genetics, 2004